The Chinese generic drug name of Pemigatinib

The generic drug name of Pemigatinib (Pemigatinib) in the Chinese market is Pemigatinib tablets, and its trade name is Dabotan or PEMAZYRE. This drug was developed and produced by Bristol-Myers Squibb (BMS) in the United States. It is mainly used to treat cholangiocarcinoma (CCA) caused by FGFR2 gene mutations or rearrangements. Pemetinib inhibits the signaling pathway of fibroblast growth factor receptor (FGFR), preventing the proliferation of tumor cells and has a certain anti-tumor effect.

The nomenclature and trademark of pemetinib vary globally, but its Chinese generic name is usually called pemetinib tablets in the domestic market, which is translated based on the international generic name of the drug. Pemetinib's generic name and trade name dalbertam allow doctors and patients to more clearly identify the drug. When using, patients should adjust the dosage according to the guidance of their doctor and strictly follow the treatment plan. Due to the relatively limited scope of use of this drug, it is usually only suitable for patients with specific types of cholangiocarcinoma and patients with FGFR2 gene abnormalities.

For doctors, knowing the generic drug name and trade name of pemetinib can help to accurately prescribe and provide treatment recommendations. For patients, knowing the generic name of a drug can help identify the drug and provide a clearer understanding of what the drug does and is used for when purchasing.

In short, pemetinib, as a new type of targeted therapy, has been approved globally and has shown good clinical effects in the treatment of FGFR2 mutation-related cancers. Although the current price is high and it is not covered by medical insurance, with the gradual popularization of the drug and the adjustment of medical policies, pemetinib may become a more widespread treatment option in the future.

Reference materials:https://go.drugbank.com/drugs/DB15102